Carl Zeiss Meditec AG (SWX:AFX)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 2.17B -58.1% |
| Revenue (ttm) | 2.01B -0.1% |
| Net Income | 87.73M -39.2% |
| EPS | 1.00 -38.9% |
| Shares Out | n/a |
| PE Ratio | 24.77 |
| Forward PE | 16.96 |
| Dividend | 0.50 (2.03%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | n/a |
| Open | 24.80 |
| Previous Close | 23.12 |
| Day's Range | 24.80 - 24.80 |
| 52-Week Range | 21.48 - 25.74 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Carl Zeiss Meditec AG
Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and p... [Read more]
Financial Performance
In fiscal year 2025, Carl Zeiss Meditec AG's revenue was 2.23 billion, an increase of 7.82% compared to the previous year's 2.07 billion. Earnings were 141.21 million, a decrease of -20.99%.
Financial numbers in EUR Financial StatementsNews
EQS-DD: Carl Zeiss Meditec AG: Peter Kameritsch, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 28.05.2026 / 14:57 CET/CEST The issuer is solely responsi...
Carl Zeiss Meditec Q2 Earnings Call Highlights
Carl Zeiss Meditec ETR: AFX reported weaker first-half results for fiscal 2025/2026 and outlined a broad restructuring plan aimed at restoring profitability over the next three years, as management po...
Carl Zeiss Meditec AG Earnings Call Transcript: Q2 2026
Six-month results showed revenue and margin declines due to currency headwinds and weak China IOL sales. The Profit Up Program targets over EUR 200 million in annual profit improvements by 2028/2029, with midterm EBITDA margin above 15% and a focus on operational efficiency and portfolio optimization.
Carl Zeiss Meditec AG Quarterly report: Q2 2026
Carl Zeiss Meditec AG has published its Q2 2026 quarterly earnings report on May 12, 2026.
Carl Zeiss Meditec AG Slides: Q2 2026
Carl Zeiss Meditec AG has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on May 12, 2026.
Carl Zeiss Meditec AG Slides: Investor presentation
Carl Zeiss Meditec AG has posted slides in relation to its latest quarterly earnings report, which was published on February 12, 2026.
Carl Zeiss Meditec AG Earnings Call Transcript: Q1 2026
Revenue and profitability declined sharply year-over-year due to currency headwinds, unfavorable product mix, and regulatory challenges in China. Guidance was suspended amid increased competition and market uncertainty, with a significant one-off impact expected in Q2.
Carl Zeiss Meditec AG Quarterly report: Q1 2026
Carl Zeiss Meditec AG has published its Q1 2026 quarterly earnings report on February 12, 2026.
Carl Zeiss Meditec AG Slides: Q1 2026
Carl Zeiss Meditec AG has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on February 12, 2026.
Carl Zeiss Meditec AG Earnings Call Transcript: Q4 2025
Revenue grew 7.8% to EUR 2.23 billion with strong order entry and record recurring revenue. EBITDA margin improved to 11.6% despite FX and tariff headwinds. Guidance for 2025-2026 targets mid-single-digit revenue growth and a 12.5% EBITDA margin, with midterm ambitions of 16%-20% margin.
Carl Zeiss Meditec AG Annual report: Q4 2025
Carl Zeiss Meditec AG has published its Q4 2025 annual report on December 11, 2025.
Carl Zeiss Meditec AG Slides: Q4 2025
Carl Zeiss Meditec AG has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on December 11, 2025.
Carl Zeiss Meditec AG Slides: Investor Presentation
Carl Zeiss Meditec AG has posted slides in relation to its latest quarterly earnings report, which was published on August 8, 2025.
Carl Zeiss Meditec AG Earnings Call Transcript: Q3 2025
Order entry and revenue grew strongly, with recurring revenue at a record high and adjusted EBITDA margin improving. U.S. tariffs and FX headwinds weighed on net income, but product launches and D.O.R.C. integration supported growth. Guidance remains for moderate revenue growth and stable margins.
Carl Zeiss Meditec AG Quarterly report: Q3 2025
Carl Zeiss Meditec AG has published its Q3 2025 quarterly earnings report on August 7, 2025.
Carl Zeiss Meditec AG Slides: Q3 2025
Carl Zeiss Meditec AG has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on August 7, 2025.
Carl Zeiss Meditec AG Completes Acquisition of Dutch Ophthalmic Research Center (D.O.R.C.); Companies Unite to Shape Ophthalmology Market
ZEISS secures regulatory approvals to acquire D.O.R.C.; companies now shift focus to integration implementation, fueling world-class innovation, and driving market expansion strategy for ophthalmic me...
Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
Acquisition will extend the company's leadership in ophthalmic medical devices market and expands its position in the vitreo-retinal surgery segment JENA, Germany , Dec. 15, 2023 /PRNewswire/ -- Carl ...